REFERENCES
- Department of Health and Human Services (DHHS) and the Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, May 4,2006. Available at: www.aidsinfo.nih.gov. Accessed July 3, 2006.
- Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among subjects with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
- Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observa-tional study. Lancet. 2003;362:22–29.
- Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
- Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treat-ment response: a meta-analysis. J Acquir Immune Defic Syndr. 2005;38:445–448.
- Ruane PJ, Parenti DM, Margolis DM, et al. Compact qua-druple therapy with the lamivudine/zidovudine combina-tion tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. HIV Clin Trials. 2003;4(4):231–243.
- Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/ lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(3):257–264.
- Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleo-side regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18)1 850–1861.
- Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combina-tion Study. J Acquir Immune Defic Syndr. 2005;38(4):417–425.
- DeJesus E, McCarty D, Farthing CF, et al. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis. 2004;39(3):411–418.
- Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25): 1865–1873.
- Ruane PJ, Richmond GJ, DeJesus E, et al. Pharmacody-namic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naive subjects infected with hu-man immunodeficiency virus. Pharmacotherapy. 2004;24(3):307–312.